The AcuPebbleTM sensor is a wearable device which is about the size of a one pound coin, weighing approximately 5 grams. It operates on the principle of acoustic sensing, measuring the sounds generated during the process of respiration. The sensor transfers the signals to a mobile device using bluetooth, and algorithms operating remotely use those signals to automatically extract parameters and biomarkers that are clinically relevant for the diagnosis of sleep apnoea. These parameters include:
Presence and severity of sleep apnoea
Duration and type of apnoeas (central vs. obstructive)
Acurable’s technology is clinically proven to be 5 times more accurate than current state-of-the-art measuring methods, allowing for much wider and more effective screening and diagnosis. It is non-invasive and easy for patients to use at home, significantly lowering the average cost of diagnosing sleep apnoea by eliminating the need for overnight stays in sleep clinics and reducing demands on doctors’ time.
Current state-of-the-art device (PSG)
About sleep apnoea
Sleep apnoea is the third most common respiratory disorder, after asthma and chronic obstructive pulmonary disease (COPD). It affects up to 2-4% of the adult population and 1-5% of the paediatric population. It causes people to repeatedly stop breathing whilst asleep, most commonly due to a narrowing or obstruction of the airway. If left untreated over time, the condition can have serious implications for health and wellbeing.
400% greater chance of heart problems and high blood pressure
Increased likelihood of type 2 diabetes
Causes 25% of road accidents in Europe, due to tiredness
Risk of complications during surgery under general anaesthesia
Secondary consequences such as reduced productivity at work and strain on relationships
Difficulties with diagnosis
A major bottleneck with diagnosis of sleep apnoea is the scarcity and high cost of diagnostic sleep clinics, where patients can be monitored wearing a set of bulky and uncomfortable sensors overnight, whilst being continuously watched by a nurse. Unfortunately diagnosing more people is not economically feasible, leading to long waiting lists and under diagnosis.
Around 3.3 million people are diagnosed in the EU and USA every year
An estimated 80-85% of cases remain undiagnosed
The AcuPebbleTM sensor addresses the problems of existing apnoea diagnosis methods and can be used as an alternative for fast and cost effective diagnosis.